Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of AM-111 in Acute Inner Ear Hearing Loss
2013-002077-21Phase 3Completed
- Sponsor
- Altamira Therapeutics
- Start
- Sep 2015
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of brimapitide in idiopathic sudden sensorineural hearing loss (ISSNHL) and tinnitus (3 arms), sponsored by Altamira Therapeutics. Started Sep 2015; status: completed.
02
Drugs
brimapitide
03
Conditions
idiopathic sudden sensorineural hearing loss (ISSNHL)tinnitus
Beyond the preview
Go deeper on 2013-002077-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-002077-21.